Stem cell research for Type 1
16/03/2021
No Comments
The US FDA has granted Fast Track Designation for VX-880, an investigational allogeneic human stem cell-derived islet cell therapy for people with Type 1 diabetes.
The US FDA has granted Fast Track Designation for VX-880, an investigational allogeneic human stem cell-derived islet cell therapy for people with Type 1 diabetes.
